Five years later, when Telaprevir was well on its way, VRTX monetized the milestones and royalties from the Mitsubishi deal for a lump sum of $105M plus $15-65M in contingencies (#msg-40126798).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”